Clinical Trials
144 trialsNCT00310180 2026-05-26
TAILORx
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01272037 2026-05-26
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02297438 2026-05-14
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT05085002 2026-05-14
A Study of Lerociclib in Participants With Advanced Breast Cancer
EQRx International, Inc.
Phase 2 Terminated
NCT03179904 2026-05-05
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT01068249 2026-04-30
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03633331 2026-04-29
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT06630325 2026-04-28
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT02095184 2026-04-15
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
University of Maryland, Baltimore
Phase NA Terminated
NCT03747042 2026-03-16
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT02712723 2026-03-11
FELINE
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT02778685 2026-02-24
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT02947685 2026-02-12
PATINA
Alliance Foundation Trials, LLC.
Phase 3 Active not recruiting
NCT02499146 2026-02-11
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Pfizer
Phase 1 Completed
NCT01674140 2026-02-10
e3
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT02520063 2026-02-06
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT02763566 2026-02-05
MONARCH plus
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02246621 2026-02-03
MONARCH 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03879577 2026-01-21
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
University of Chicago
Phase 2 Active not recruiting
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT03673124 2025-12-23
Ribociclib and Letrozole Treatment in Ovarian Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT02101788 2025-11-13
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT04272801 2025-10-22
POWER
University of Virginia
Phase 2 Active not recruiting
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT04191382 2025-09-18
AMEERA-4
Sanofi
Phase 2 Terminated
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT04478266 2025-09-11
AMEERA-5
Sanofi
Phase 3 Terminated
NCT03099174 2025-06-24
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT00601900 2025-05-23
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02764541 2025-05-07
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT00265759 2025-04-23
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT05206448 2025-04-15
CLC II
University of Iowa
Phase 4 Active not recruiting
NCT00999804 2025-03-12
HELEX
Baylor Breast Care Center
Phase 2 Active not recruiting
NCT01958021 2025-03-07
MONALEESA-2
Novartis
Phase 3 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT03774472 2025-02-17
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04294225 2025-01-28
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
Mayo Clinic
Phase 2 Completed
NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01897441 2024-12-24
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
Albert Einstein College of Medicine
Phase NA Terminated
NCT03644186 2024-12-13
TOUCH
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT01870505 2024-12-09
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02491983 2024-12-09
PARSIFAL
MedSIR
Phase 2 Completed
NCT01740427 2024-11-14
PALOMA-2
Pfizer
Phase 3 Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT02228681 2024-09-19
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT01296555 2024-07-31
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Genentech, Inc.
Phase 1 Terminated